metaEvidence - overview


			DCR
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population
versus docetaxel
	atezolizumab alone vs. docetaxel	2	-
	avelumab alone vs. docetaxel	1	-
	nivolumab alone vs. docetaxel	1	-
	Tislelizumab vs. docetaxel	1	-
mNSCLC - L2 - EGFR mutant metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - EGFR mutant
versus osimertinib
	durvalumab plus osimertinib vs. osimertinib	1	-
mNSCLC - L2 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 negative
mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive
versus docetaxel
	atezolizumab alone vs. docetaxel	1	-
	avelumab alone vs. docetaxel	1	-
	pembrolizumab (10mg/kg) vs. docetaxel	2	-
	pembrolizumab (2mg/kg) vs. docetaxel	2	-
versus Standard of Care (SoC)
	durvalumab alone vs. Standard of Care (SoC)	1	-
non squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) non squamous cell - mNSCLC - L2 non squamous - mNSCLC - L2 - all population
versus docetaxel
	nivolumab alone vs. docetaxel	1	-
squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) squamous cell - mNSCLC - L2 squamous - mNSCLC - L2 - all population
versus docetaxel
	nivolumab alone vs. docetaxel	1	-